Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus vinorelbine versus vinorelbine in HER2-negative advanced breast cancer
ChiCTR2300069004Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of anlotinib and vinorelbine in breast cancer (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
anlotinibvinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2300069004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069004.